Siemens Healthineers has introduced two new assays for quick diagnosis of acute myocardial infarction or heart attack, following approval from the US Food and Drug Administration (FDA).
The High-Sensitivity Troponin I assays (TnIH) for the Atellica IM and ADVIA Centaur XP/XPT in-vitro diagnostic analysers are designed to detect low cardiac troponin I levels in serum or plasma.
Said to demonstrate 99% precision, the assays can also identify small changes in a patient’s troponin level because of repeat testing.
Early diagnosis is critical as the heart muscle starts dying within 30-60 minutes following the blockage of blood flow to the heart.
Since dying heart muscle releases troponin into the bloodstream, the compound is considered as an indicator of a heart attack.
Out of the more than eight million visits to emergency departments in the US, only 5.5% lead to serious diagnoses such as heart attacks.
The new assays are expected to support testing initiatives by using data to correctly triage patients early or rule out myocardial infarctions.
Zuckerberg San Francisco General Hospital and Trauma Center, Clinical Chemistry and Toxicology chief Alan Wu said: “If we can do a more efficient job at triaging patients to receive the proper level of care and to discharge the patients who do not need to stay in the emergency department, this will have a tremendous economic advantage for our healthcare system.”
According to Siemens, the TnIH assays leverage the company’s technology with three new monoclonal antibodies and are set to provide better patient care with high-sensitivity cardiac troponin detection.
The Siemens portfolio for troponin detection additionally includes Atellica IM, ADVIA Centaur, Dimension EXL and Dimension Vista TNIH assays that are also designed to detect lower troponin levels.